Genelux Investor Presentation Deck
Olvi-Vec: Ideal Backbone for Combination Therapy
Converts Tumor Microenvironment to Inflammatory "Hot Spot"
Induction of acute inflammatory
cytokines
GENELUX
(Th1-type related)
VIRO-15 Study
Endogenous PD-L1 expression in
ovarian tumor is low, hence limiting
target by
Fold-change from Baseline
anti-PD-1/PD-L1 therapy
Rodriguez-Freixinos et al. J Clin Oncol 36, 2018
(suppl; abstr 5595)
6
N
Up Regulates Immunomodulatory Target Proteins, such as PD-L1
Percentage of cases
Baseline W1D5 W2D10 W3D17
80%
100% 1
60%
PIL-6
CRP
SAA
TNF-α
40%
PIL-15
TARC
IP-10
20%
0%
n=24
(25%)
(46%)
PD-L1 expression
<1%
<20%
[20%-50%]
>50%
NCT01443260/TUE Study
MEDCOM RESAMPLED-Vedute komp
Baseline
MEDCOM RESAMPLED-Verlustbehate kompeniet
Baseline
Massive inflammatory
response after cycle 1 of
virus treatment
PD-L1: VIRO-15 Study
Post treatment (20d)
Strong PD-L1 staining at
the tumor-stromal interface
38View entire presentation